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TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC) 
with mutations occurring in over two third of cases, but the prognostic significance of these 
mutations remains elusive. In the current study, we evaluated a novel computational approach 
termed Evolutionary Action (EAp53) to stratify patients with tumors harboring TP53 mutations as 
high or low risk, and validated this system in both in vivo and in vitro models. Patients with high 
risk TP53 mutations had the poorest survival outcomes and the shortest time to the development of 
distant metastases. Tumor cells expressing high risk TP53 mutations were more invasive and 
tumorigenic and they exhibited a higher incidence of lung metastases. We also documented an 
association between the presence of high risk mutations and decreased expression of TP53 target 
genes, highlighting key cellular pathways that are likely to be dysregulated by this subset of p53 
mutations which confer particularly aggressive tumor behavior. Overall, our work validated 
EAp53 as a novel computational tool that may be useful in clinical prognosis of tumors harboring 
p53 mutations.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer 
worldwide and accounts for over 45,000 new cases annually in the United States (1, 2). 
Since TP53 is the most frequently mutated gene in HNSCC, genomic alterations in this gene 
are key events in the development and progression of this disease (3–6).
Multiple studies have demonstrated that TP53 mutations are prognostic for poor outcomes in 
HNSCC, yet molecular testing for TP53 alterations has not become routine in clinical 
practice (7–11). Although several classifications systems have been described, the main 
limitation of TP53 as a prognostic biomarker is the lack of a reliable system to accurately 
assess the functional and clinical impact of specific mutations (10). Whereas most 
alterations involving tumor suppressor genes render them nonfunctional through truncating 
mutations or deletions, p53 is unique in that there is a strong selection bias for missense 
mutations, particularly within the DNA-binding domain. P53 mutation can result in loss of 
wild type functions through either the loss of DNA-binding activity of p53 responsive 
elements or a dominant negative effect where the mutated allele binds and inhibits the 
remaining functional wild-type allele(12). Moreover, some mutant p53 displays oncogenic 
properties, termed “gain of function” (GOF), which are independent of wild-type p53 
function(13). Accordingly, gain of function p53 mutants can enhance cell transformation, 
increase tumor formation in mice and confer cellular resistance to chemotherapy(14, 15).
While this GOF activity has been well characterized in cancer for five ‘hotspot’ or 
frequently altered p53 amino acids, 175, 245, 248, 273, and 282, our work indicates that non 
‘hotspot’ mutations can also confer GOF activity(16). Therefore we hypothesized that there 
is a subset of mutations that are particularly deleterious to p53 function resulting in a GOF 
phenotype and are associated with adverse outcomes in patients with HNSCC.
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In an effort to predict which TP53 mutations are highly deleterious, we extended the 
Evolutionary Trace (ET) approach, an extensively validated method to identify key 
functional or structural residues in proteins(17). This is achieved by assigning every 
sequence position a grade of functional sensitivity to sequence variations, defined by 
whether its evolutionary substitutions correlate with larger or smaller phylogenetic 
divergences. Residues with large ET grades typically cluster structurally into evolutionary 
‘hot-spots’ that overlap and predict functional sites(18). In large scale validation studies, 
motifs made of top-ranked ET residues predict function in protein structures(19), accurately 
enough to anticipate enzyme substrates (20).
We have hypothesized that the ET method would assess the impact of TP53 missense 
mutations. The impact should be greater when the mutated residues are more evolutionarily 
sensitive to sequence variations, i.e. have a larger ET grade, and also when the amino acid 
change is least conservative, so the mutational impact is the largest. These two components 
were computed and combined into a single score, called Evolutionary Action EA(21). This 
action has been shown to correlate linearly with loss of protein function in test systems and 
with morbidity in Mendelian diseases, as well as apply across protein coding variations 
population-wide. To apply this Evolutionary Action to TP53 mutations in HNSCC, we 
further developed a scoring system (EAp53) to stratify TP53 missense mutations into high 
and low risk.
The goals of this study were to evaluate the ability of EAp53 to identify a subset of TP53 
mutations in HNSCC that are associated with the worst patient outcomes and to validate the 
impact of these mutations in laboratory based models. We found that EAp53 could identify 
mutations with GOF phenotypes, termed high risk, that are highly prognostic of poor overall 
survival, progression-free survival, and the development of distant metastasis in two patient 
cohorts. Furthermore, high risk mutations were found to be associated with increased 
cellular invasion, tumorigenicity, and propensity for distant metastases in both in vitro and 
in vivo models, thereby associating functionally significant TP53 mutations with outcomes 
of patients harboring high risk TP53 alterations. These oncogenic p53 mutations also had a 
distinct mRNA expression profile, which suggests high risk p53 mutants regulate unique 
cellular pathways at the transcriptional level. These findings highlight the need for further 
evaluation of the EAp53 scoring system as prognostic biomarker in both retrospective and 
prospective data sets. Finally this study emphasizes the need for continued investigation into 
the cellular pathways driving the oncogenic phenotype of these high risk p53 mutations 
which could lead to the identification of novel therapeutics targets and ultimately 
personalization of cancer treatment based on p53 mutational status.
Methods
Patient Selection and Tissue Procurement for the EAp53 Method
Training set: A cohort of patients was identified from the TCGA HNSC project that had 
HPV negative tumors (See supplemental methods for additional details) and underwent 
surgical resection alone (n=103) or surgery followed by post-operative radiation (n=65). 
Patient and tumor characteristics along with outcome data were extracted from TCGA 
HNSC supplemental data.
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Validation set: A cohort of patients with HNSCC treated with surgery followed by post-
operative radiation at The University of Texas MD Anderson Cancer Center (UTMDACC) 
from 1992 – 2002 was identified (n=96). Clinical records were reviewed retrospectively and 
TP53 gene status was determined according to a protocol approved by the institutional 
review board at UTMDACC. Patients who received chemotherapy were excluded. Clinical 
and pathologic factors were recorded, including patient age, sex, T and N stage, surgical 
margin status, and extracapsular lymph node extension (ECE). Survival outcomes including 
overall and disease free survival along with time to distant metastases were also determined.
DNA Isolation
Samples were isolated using three different methods depending on the platform used to 
perform the sequencing of TP53. The techniques used either snap-frozen tumor sample or 
formalin-fixed, paraffin-embedded tissue and the detailed description of the extraction 
method is included in the supplemental methods.
TP53 Sequencing
As mentioned above three different techniques were utilized to determine TP53 sequence. In 
each assay, the coding regions and surrounding splice sites from exons 2–11 of the TP53 
gene were evaluated via direct sequencing from genomic DNA and a detailed description is 
included in the supplemental methods.
Calculation of the EAp53 scores
The evolutionary action (EA) scores for each TP53 mutation were calculated based on a 
simple model of the phenotype-genotype relationship, which hypothesizes that protein 
evolution is a continuous and differentiable process. Accordingly, the genotype (γ) and the 
fitness phenotype (φ) will be related by φ =f (γ), and the phenotypic impact of any mutation 
at residue i (evolutionary action) will be the product of two terms: the sensitivity of p53 
function to residue variations (∂f/∂γi) and the magnitude of the substitution (Δγi). The term 
∂f/∂γi was measured by importance ranks of the Evolutionary Trace method (22, 23), 
according to which, residues that vary amongst closer homologous sequences are ranked less 
important than those that only vary amongst distant homologous sequences. The magnitude 
of the substitution (Δγi) was measured by ranks of amino acid substitution odds(24), 
however, these odds were computed for different deciles of the evolutionary trace grade at 
the substituted position. We normalized the product to become percentile scores for p53 
protein, for example, an EA score of 68 implied that the impact was higher than 68% of all 
possible amino acid substitutions in p53.
Statisical Classification by EAp53
Missense mutations were scored by EAp53 from 0–100 with higher scores representing 
more deleterious alterations. Wildtype p53 (wtp53) sequences were scored as zero since this 
is the normally functioning protein, see supplemental data for additional description of 
scoring system. Additionally to obtain scores for individual p53 mutations, an EAp53 server 
is available at http://mammoth.bcm.tmc.edu/EAp53.
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Univariate Cox proportional hazards models were used to estimate hazard ratios and their 
corresponding p-values for all risk factors in the training set. The optimal threshold for 
EAp53 to stratify patients between favorable and poor outcomes was identified using the 
training data set, and the p-value for the estimated hazard ratio was adjusted (25). The 
threshold discretizes evolutionary action into low-risk and high-risk patients.
Multivariate Cox proportional hazards model was created with all risk factors except the 
discretized evolutionary action factor. Rank-based procedure was used based on the Cox 
proportional hazards model to determine the best threshold for evolutionary action in a 
multivariate model(26). A Cox proportional hazard model using all risk factors as above 
along with the discretized evolutionary action factor is created to estimate hazard ratios for 
each risk factor and their p-values. The p-value for the discretized evolutionary action factor 
is adjusted to account for using the data to first determine the cut point. We remove 
covariates from the model one by one and repeat the above procedure until a model is 
developed containing risk factors that have hazard ratios which are significant and the p-
values for the coefficient of the factors in the final model are < 0.05.
Next, the threshold established in the training dataset was applied to the validation dataset to 
classify TP53 mutations as either low or high risk. Using survival time, univariate Cox 
proportional hazards model were built for each risk factor using the validation data set to get 
estimates for hazards ratios and their p-values. No adjustments to the p-values were 
necessary. Cox proportional hazard model was also built containing all the risk factors 
including the EAp53 threshold determined in the test set and reducing the model by 
removing the covariate with the largest p-value in a stepwise manner until the final model 
only contained significant risk factors.
We used the discretized evolutionary action data to perform log-rank tests to determine 
differences in time to death between low-risk and high-risk TP53 patients. The above 
analyses for the validation data set were reproduced with disease-free survival as an 
outcome and time to metastases as an outcome.
Site-directed Mutagenesis and TP53 Constructs
Mutations with a variety of EA scores (Supplementary Table 3) were produced using a 
QuickChange-II Site-Directed Mutagenesis Kit (Agilent Technologies), starting with 
wildtype human p53 cDNA with polymorphic region 72 containing arginine previously 
cloned into a pBabe retroviral expression vector (pBABEpuro, Addgene). Primer sequences 
used for mutagenesis are shown in Supplementary Table 3. All mutagenesis steps were 
performed according to the manufacturer’s protocol. Mutations were confirmed by Sanger 
sequencing at the MD Anderson Cancer Center DNA core facility.
Generation of the HNSCC Stable Cell Lines
Two HNSCC cell lines UMSCC1 and PCI13 were selected for their lack of p53 expression 
due to a splice-site in UMSCC1 (hg19:chr17:7578370C>T) and a deletion in PCI13 
(hg19:chr17:7579670_7579709del). UMSCC1 was provided by Dr. Thomas Carey 
(University of Michigan). PCI13 was acquired from Dr. Jennifer Grandis (University of 
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Pittsburgh). The genomic identities of the cell lines were authenticated using short tandem 
repeat analysis (27). Cells stably expressing TP53 constructs were generated as described 
previously and a detailed description of the technique is included in the supplemental 
methods (28).
Immunoblotting
Western blotting was performed using standard techniques previously described (27) and 
primary antibodies to anti-p53 (Santa Cruz Biotechnology, sc-126), anti-p21 (Calbiochem, 
OP64) and beta-actin (sc81178, Santa Cruz Biotechnology) were used.
Invasion Assay
BD BioCoat Matrigel Invasion Assays were used following the manufacturer’s protocol and 
a detailed description is included in the supplemental methods. Each cell line was run in 
triplicate. 3T3 NIH cells were used as an invasion control as these cells characteristically 
migrate but do not invade. The low and high risk represents a composite of three mutations, 
F134C, A161S, and Y236C and four mutations, R175H, H179Y, C238F, G245D, 
respectively and the results represent two independent experiments.
Cell Proliferation Assay
Cell proliferation was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay as previously described(29). Briefly, the cells 
were seeded at different densities and grown in a medium containing 10% FBS in 96-well 
tissue culture plates. After a 24-hour attachment period, the plates were assigned to different 
time points to obtain linear optical density (O.D.). Cells were then incubated for 3 hours in 
medium containing 2% FBS and 0.25 mg/mL MTT, after which the cells were lysed in 200 
µL dimethylsulfoxide (DMSO) to release the formazan. The conversion of MTT to formazan 
was quantified with an EL-808 96-well plate reader (BioTek Instruments, Winooski, VT) set 
at an absorbance of 570 nm. The OD values were then obtained and analysed to determine 
the % of cell viability.
Orthotopic Nude Mouse Model of Oral Cavity Cancer
All animal experimentation was approved by the Animal Care and Use Committee (ACUC) 
of the University of Texas MD Anderson Cancer Center. Our orthotopic nude mouse model 
of oral cavity cancer has been previously validated and a detailed description of the 
technique is included in the supplemental method (30). The results represent three 
independent experiments with the low and high risk mutations including two mutations 
F134C and A161S and four mutations, R175H, H179Y, C238F, and G245D respectively.
Tail Vein Model
The experimental metastatic tail vein injection model was performed using standard 
techniques previously described and a detailed description is included in the supplemental 
methods (31). The results represent four independent experiments with PCI13 and UMSCC1 
cell lines harboring low risk mutations: F134C or A161S, high risk mutations: R175H, 
C238F or G245D, pBabe, or wtp53.
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mRNA expression arrays
Total RNA was isolated from cell lines by using Tri-reagent and hybridized to Affymetrix 
GeneChip Human Exon 1.0ST Arrays (Affymetrix) according to manufacturer’s instructions 
and a detailed description is included in the supplemental methods. The one hundred and 
two p53 target genes were identified and validated through rigorous literature review (L 
Donehower unpublished data). The difference in expression between pBabe and each of 
other groups was calculated and heatmaps were generated depicting these expression 
patterns target gene and 49 selected genes.
Quantitative Reverse Transcription PCR (RT-qPCR) Analyses
Validation of the mRNA expression array for two TP53 target genes (p21 and Notch1) was 
performed by RT-qPCR. Total RNA was isolated from HNSCC cell lines using Trizol 
method. Reverse transcription was performed using the high capacity cDNA Reverse 
Transcription kit (Applied Biosystem) according to the manufacturer’s protocol and a 
detailed description is included in the supplemental methods.
Results
Patient characteristics and follow-up in the training and validation set
Analysis of the TCGA HNSCC cohort identified 168 patients with non-HPV-associated 
tumors harboring either missense mutations or wildtype p53 for our training cohort. The 
majority of these patients presented with advanced T stage (70%) while only 30% of 
patients presented with advanced neck disease (Supplemental Table 1). The median survival 
time was 2.96 years and median follow up time was 2.49 years.
Ninety-six patients treated at MD Anderson Cancer Center for HNSCC through surgical 
resection and post-operative radiation comprised an independent validation set for the 
EAp53 scoring system. The majority of patients had advanced T (76%) or N stage (54%), 
and nearly half had aggressive pathologic features (Supplemental Table 1). The median 
survival time and median follow-up time was 5.49 and 7.66 years respectively.
TP53 mutation in the patient cohorts
One hundred and forty-three TP53 missense mutations were identified in 127 patients in the 
training set while fifty missense mutations were identified in 47 patients in the validation 
cohort (Supplementary Table 2 and 3). The majority of these missense mutations were 
within the DNA-binding domain. Furthermore 34% and 38% of the mutations were located 
in the well-characterized TP53 hotspot sites, 175, 245, 248, 273, 282 in the training and 
validation sets, respectively.
Determination of EAp53 Threshold, Risk Models and Survival Analysis
Age, disease site, T-stage, N-stage, and TP53 missense mutations were assessed as risk 
factors for poor overall survival in the training set. The initial comparison analyzed three 
groups independently, low EAp53 score, high EAp53 score, and wildtype p53. Univariate 
analysis in the training set revealed that the low EAp53 score mutations, i.e. low risk, and 
wild type were not statistically different whereas the high EAp53 score mutations, termed 
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high risk mutations, appeared to be distinct from the other two groups (Table 1 and Figure 
1). Given the similar outcomes, patients with tumors having low risk mutations were 
combined with wtp53. After univariate analyses an EA threshold of greater than 74.39 
identified a group of 82 patients with high risk mutations associated with a significantly 
decreased overall survival compared to 86 patients in the low risk group, p=0.008 (Table 1). 
A rank-based procedure based on the Cox proportional hazards ratios in a multivariate 
model was then applied to the training set, and identified an EA threshold of 77.78, p=0.009 
(Table 2). Because this model relies on a threshold specific to the TCGA data, the range 
from 74.39 – 77.78 should contain the valid threshold. Therefore we applied a threshold of 
75 to the validation set to determine low and high risk individuals. With this threshold 
established, this prognostic model was validated in an independent data set and patients with 
HNSCC harboring high risk mutations (n=33) had significantly decreased overall and 
disease free survival relative to the low risk group (n=63), p=0.030 and p=0.011 (Table 1 
and 2). Furthermore this survival difference appeared to be associated with the development 
of distant metastases, p=0.059 (Table 2). Additionally, when patients that achieved 
locoregional control were analyzed, a log rank test revealed tumors with high risk mutations 
were still associated with increased rate of distant metastases, p = .00006. Additionally in a 
multivariate analysis using backward variable selection, the final model identified N stage ≥ 
N2b, p=.0064, and high risk mutations, p=.05 as predictors of distant metastases.
Survival analysis using the Kaplan Meier method revealed high risk TP53 mutations were 
associated with poor outcomes for overall survival, disease-free survival, and distant 
metastasis, p=0.04, 0.04, and 0.09 respectively (Figure 2a-c).
High Risk TP53 mutations are more invasive in vitro and tumorigenic in vivo
To determine the impact of the high risk TP53 mutations in pre-clinical models, several low 
and high risk TP53 mutant transcripts were stably expressed in two HNSCC cell lines that 
do not endogenously express p53 due to bi-allelic alterations including somatic mutations 
(Supplementary Figure 1). Cell lines expressing high risk TP53 mutations, including 
R175H, H179Y, C238F, and G245D were significantly more invasive than cells expressing 
wtp53, p53 null (pBabe), or low risk mutations, A161S, F134C, and Y236C, p=0.001, 
p=0.05, and p=0.03 respectively (Figure 3 Panel A). Assessment of cell motility by scratch 
assay revealed cells bearing high risk TP53 mutants, R175H, G245D, and C238F were 
significantly more motile than cells expressing wtp53, pBabe, or low risk TP53 mutation, 
A161S, p=0.04, p=0.01, and p=0.002 respectively (Figure 3 Panel B). In contrast to the 
increased cellular invasion and motility observed in the high risk TP53 mutations, the rate of 
proliferation was independent of TP53 status (Supplemental Figure 2). From these results, 
we concluded that the expression of high risk mutations is associated with greater migration 
and invasion, suggesting a gain of function phenotype.
To validate our in vitro data, the isogenic p53 mutant cell lines were introduced into an 
orthotopic nude mouse tongue cancer model. Although neither the rate nor time of tumor 
formation were different across various p53 statuses, cell lines that expressed high risk TP53 
mutations formed significantly larger tumors compared to cells that expressed wtp53, 
pBabe, or low risk p53 mutations (Supplemental Table 4, Figure 3 Panel c and d).
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High Risk TP53 mutations have higher propensity for lung metastases
To directly evaluate the contribution of high risk p53 mutations in the development of 
distant metastases, we used the experimental metastatic tail vein injection model. Animals 
injected with tumor cells carrying high risk mutations, R175H, C238F or G245D, had 
significantly more grossly visible pulmonary metastases when compared to those injected 
with cells with low risk p53 mutations, F134C or A161S, p=0.01, pBabe, p=0.008, and 
wtp53, p=0.004 (Figure 4 Panel a & b). Additionally animals injected with high risk mutant 
bearing cells had higher numbers of microscopic metastases (Figure 4 Panel c & d).
High risk p53 mutations have a distinct expression profile of know p53 target genes
In an effort to identify genes or pathways responsible for the increased tumorgenicity and 
metastases associated with high risk TP53 mutations, we performed mRNA expression 
arrays of cells harboring either wtp53, pBabe, low risk mutation, A161S, or high risk 
mutation, C238F. After standardizing gene expression to the control p53 null cell line, 
pBabe, an analysis of 102 p53 target genes revealed wtp53 cells had an elevated level of 
expression in 61% (62/102) of the targets genes whereas the high risk mutant expressing 
cells suppressed expression in the majority of the same genes. In contrast, the expression 
pattern of cells expressing a low risk mutation was more similar to that of wtp53 cells as 
revealed by the hierarchal clustering (Figure 5 Panel a). Upon further analysis of the entire 
expression array, 49 genes were differentially expressed with wtp53 and the high risk 
mutation having elevated and suppressed levels of expression, respectively, relative to p53 
null, pBabe cells (Figure 5 Panel b). Within these 49 genes, three p53 target genes p21, 
Notch1and BTG2 were shown to have this differential expression profile. Quantitative RT-
PCR validated the elevated level of expression of these three genes in cells expressing 
wtp53 or low risk p53 mutations, A161S and Y236C, and the significantly decreased 
expression in cells bearing high risk mutations, C238F and G245D, relative to cells without 
p53 expression (Figure 5 Panel c).
Discussion
An appropriate method for classifying TP53 mutations and assessing the functional impact 
of these alterations has been sought for decades, yet a suitable classification scheme remains 
elusive. Therefore, we have utilized a novel computational method that considers 
evolutionary variations to predict the functional impact of TP53 mutations. We hypothesized 
this model could identify missense mutations with the greatest functional impact which 
would translate to decreased patient survival outcomes. Our analysis of two patient datasets 
along with in vitro and in vivo models supports TP53 mutational status as a prognostic 
biomarker in HNSCC.
Currently, TP53 mutational status is not incorporated into the clinical evaluation of HNSCC 
patients, even though previous reports have identified TP53 mutations associated with poor 
patient outcomes(8, 10, 11). These previous systems either heuristically stratified mutations 
based on their potential impact on the p53 molecule and could not be validated in these two 
cohorts (Supplemental Table 5 and 6 and Supplemental Figure 3 and 4) or stratified TP53 
mutations by presence of a copy number loss using a multi-tiered genomic approach(11). In 
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contrast, EAp53 is based on a formal model of evolution which has been shown to perform 
well against other approaches(17, 21), and has been refined here to specifically evaluate the 
clinical impact of TP53 mutations. Our results show that patients with HNSCC harboring 
high risk TP53 mutations had significantly worst overall survival, which was validated in a 
second patient cohort.
In addition to the development and validation of a novel method for stratifying TP53 
mutations, we evaluated several low and high risk p53 mutations in two isogenic HNSCC 
cell lines in both in vitro and in vivo models. These results corroborated that EAp53 can 
identify a subset of high risk mutations that are more invasive and tumorigenic than the loss 
of p53, implying an oncogenic or GOF phenotype. Additionally as seen in the patient cohort, 
the high-risk mutations had a greater propensity for distant metastases in an experimental 
metastatic model. Furthermore the low risk mutations were most similar to wtp53 in both in 
vivo and in vitro models suggesting that these alterations may maintain some residual tumor 
suppressive functions. While previous classification systems in HNSCC have identified 
mutations associated with poor outcomes, these studies have not correlated the potential 
functional impact of these mutations at the cellular level (7, 8, 10). Additionally previous 
functional studies in yeast that determined the transactivational activity of TP53 mutations, 
classified most alterations as nonfunctional including many hotspot mutations considered to 
have GOF properties(32). Given the limitations of these previous studies, we were able to 
identify patients with tumors harboring mutations associated with decreased survival and 
confirm these same alterations have oncogenic properties in pre-clinical assays.
Analysis of mRNA expression arrays revealed cells with wtp53 had elevated levels of 
expression in the majority of TP53 target genes while cells bearing high risk mutations had 
suppressed levels of expression in these same genes which may partially explain the gain of 
function properties observed with these mutations. The low risk mutations modulated the 
expression of TP53 target genes more similarly to wtp53 again, implying some residual 
wildtype function. Suppressed target gene expression in mutations that have GOF 
phenotypes corroborates previous studies that have postulated alteration of the p53 
transcriptome is a potential mechanism of GOF activities (33, 34).
In conclusion, the EAp53 system appears to identify high risk mutations associated with 
decreased survival and increased development of distant metastases in HNSCC patients 
which is corroborated in both in vitro and in vivo studies of invasion, tumorigenicity, and 
development distant metastases. In order to adopt EAp53 into clinical practice, it will be 
necessary to confirm the prognostic utility in prospective clinical trials with HNSCC 
patients managed with the therapeutic standard of care. Furthermore continued investigation 
into the cellular pathways driving the oncogenic phenotype of these high risk p53 mutations 
is necessary which could lead to the identification of novel therapeutics targets and 
ultimately personalization of cancer treatment based on p53 mutational status.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. EAp53 identifies two functionally distinct groups of p53 mutations
Patients with tumors harboring high risk EAp53 (n=83) mutations have a decreased overall 
survival relative to low risk EAp53 (n=44) mutations and wtp53 (n=41). In contrast, patients 
with low risk EAp53 mutations appear to have similar survival outcomes to wtp53.
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Figure 2. EAp53 can identify patients with decreased survival outcomes in HNSCC
Log rank tests of Kaplan Meir survival plots for a cohort of patients treated with surgery 
followed by radiation therapy validated that EAp53 can identify patients with high risk 
mutations that are associated with a decreased overall and disease free survival, p=0.041 and 
0.036 respectively (Panel A and B). Additionally high risk EAp53 mutations appear to be 
associated with an increased rate of distant metastases p=0.092 (Panel C).
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Figure 3. High Risk TP53 mutations are more invasive in vitro and tumorigenic in vivo
Matrigel invasion assays were were performed on PCI13 isogenic HNSCC cell line 
expressing either high or low risk mutations TP53 mutations, wtp53, pBabe empty vector 
control. The low and high risk series are a composite of three mutations, F134C, A161S, and 
Y236C and four mutations, R175H, H179Y, C238F, G245D, respectively and the results 
represent two independent experiments (Panel A). Scratch assays were performed on PCI13 
isogenic HNSCC cell line expressing wtp53, pBabe empty vector control, low risk mutation 
A161S(shown), or high risk mutations, G245D, R175H, C238F(shown). Percent scratch 
closure represents two independent experiments and the mean closure is represented for 
each p53 status. PCI13 and UMSCC1 isogenic cell lines expressing either wtp53, pBabe, 
low risk mutations, A161S or F134C or high mutations, R175H, H179Y, C238F, or G245D 
were introduced into the orthotopic model of tongue cancer (Panel C and D).
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Figure 4. High risk TP53 mutations are associated with increased development of lung 
metastases
UMSCC1 and PCI13 isogenic cell lines harboring either wtp53, pBabe, low or high risk 
mutations were injected into tail vein of nude mice. The low and high risk series are a 
composite of two mutations, A161S or Y236C and three mutations, R175H, C238F, or 
G245D, respectively and the results represent two independent experiments. Data labels in 
columns correspond to number of animals in each group. Macroscopic nodules can be 
appreciated in the representative images from the lungs of mice top from the pBabe, low and 
high risk groups (Panel B). The frequency of microscopic lung metastases was assessed by 
hematoxylin and eosin in animals from the wtp53, pBabe, low risk and high risk groups 
(Panel C & D).
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Figure 5. Suppression of downstream TP53 target genes by high risk TP53 mutations
Heat map depicting expression for 102 TP53 target genes relative to pBabe (Panel A). 
Analysis of the entire expression array relative to the pBabe identified 49 genes that had 
significantly different levels of expression in both the wildtype and the high risk mutation. 
This analysis identified three known TP53 targets genes, p21, Notch1, and BTG2 as 
significantly overexpressed and under expressed in the wildtype and high risk mutation 
respectively (Panel B). Quantitative RT-PCR of p21 and Notch1 in wtp53, pBabe, two low 
risk mutations, A161s and Y236C, and two high risk mutations, C238F and G245D (Panel 
C). ƚ and ‡ indicate significant overexpression and suppressed expression relative to pBabe 
respectively.
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